Harrow (HROW) Q1 2026 Earnings Report and Transcript Summary
Harrow reported $44.2 million in consolidated revenue for Q1 2026, which is expected to be the lowest of the year due to a discrete reduction from high-deductible patient mix issues affecting VEVYE's performance. Adjusted EBITDA was negative at -$12.7 million.
Tickers: $HROW
Topics: adjusted_ebitda market_share prescription_growth revenue